TRIB - Trinity Biotech Plc

0.6645
-0.041   -6.095%

Share volume: 55,836
Last Updated: 04-23-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$0.70
-0.04
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 29%
Dept financing 23%
Liquidity 63%
Performance 37%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-9.96%
1 Month
9.53%
3 Months
-27.35%
6 Months
-33.55%
1 Year
3.81%
2 Year
-63.69%
Key data
Stock price
$0.66
P/E Ratio 
0.00
DAY RANGE
$0.65 - $0.69
EPS 
$0.11
52 WEEK RANGE
$0.50 - $3.44
52 WEEK CHANGE
-$6.14
MARKET CAP 
4.493 M
YIELD 
N/A
SHARES OUTSTANDING 
2.258 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
0.67
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$88,634
AVERAGE 30 VOLUME 
$135,972
Company detail
CEO: Aris Kekedjian
Region: US
Website: trinitybiotech.com
Employees: 480
IPO year: 1995
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company sells its products through its direct sales force; and a network of independent distributors.

Recent news